Patents by Inventor Sunghoon Ma
Sunghoon Ma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11980078Abstract: A display device is provided. The display device includes: a substrate, a first display area in which a plurality of main sub-pixels are arranged on the substrate, and a second display area in which a basic unit is arranged, the basic unit including an auxiliary light-emitting area, in which a plurality of auxiliary sub-pixels are arranged on the substrate, and a transmission portion, wherein each of the plurality of auxiliary sub-pixels includes a pixel electrode on the substrate, an intermediate layer on the pixel electrode, and an opposite electrode on the intermediate layer, wherein intermediate layers of auxiliary sub-pixels for emitting light of a same color from among the plurality of auxiliary sub-pixels are connected to each other.Type: GrantFiled: June 1, 2023Date of Patent: May 7, 2024Assignee: Samsung Display Co., Ltd.Inventors: Jongwon Chae, Moosoon Ko, Jinseock Ma, Sunghoon Moon, Sewan Son, Sangshin Lee, Yongje Jeon, Jingoo Jung
-
Patent number: 11932606Abstract: This invention provides, among other things, compounds useful for treating diseases such as fibrosis and/or cancer, pharmaceutical formulations containing such compounds, as well as combinations of these compounds with at least one additional therapeutic agent.Type: GrantFiled: July 31, 2018Date of Patent: March 19, 2024Assignee: The Regents of the University of CaliforniaInventors: David M. Jablons, Wei Xu, Liang You, Shu Liu, Shendong Yuan, Sunghoon Ma, Morrison Mac
-
Publication number: 20230382917Abstract: Heterocyclic compounds useful as antagonists of adenosine receptors, and methods of treatment of diseases using antagonists of adenosine receptors are disclosed herein. Also disclosed herein are pharmaceutical compositions and methods of administration of heterocyclic antagonists of adenosine receptors and processes for producing heterocyclic antagonists of adenosine receptors.Type: ApplicationFiled: May 25, 2023Publication date: November 30, 2023Inventors: Sunghoon Ma, Yong Wang, Wei Xu
-
Patent number: 11718622Abstract: Heterocyclic compounds useful as antagonists of adenosine receptors, and methods of treatment of diseases using antagonists of adenosine receptors are disclosed herein. Also disclosed herein are pharmaceutical compositions and methods of administration of heterocyclic antagonists of adenosine receptors and processes for producing heterocyclic antagonists of adenosine receptors.Type: GrantFiled: March 15, 2021Date of Patent: August 8, 2023Assignee: Exelixis Inc.Inventors: Sunghoon Ma, Yong Wang, Wei Xu
-
Publication number: 20230192621Abstract: This invention provides, among other things, compounds useful for treating diseases such as fibrosis and/or cancer, pharmaceutical formulations containing such compounds, as well as combinations of these compounds with at least one additional therapeutic agent.Type: ApplicationFiled: July 31, 2018Publication date: June 22, 2023Inventors: David M. JABLONS, Wei XU, Liang YOU, Shu LIU, Shendong YUAN, Sunghoon MA, Morrison MAC
-
Publication number: 20210292332Abstract: Heterocyclic compounds useful as antagonists of adenosine receptors, and methods of treatment of diseases using antagonists of adenosine receptors are disclosed herein. Also disclosed herein are pharmaceutical compositions and methods of administration of heterocyclic antagonists of adenosine receptors and processes for producing heterocyclic antagonists of adenosine receptors.Type: ApplicationFiled: March 15, 2021Publication date: September 23, 2021Inventors: Sunghoon Ma, Yong Wang, Wei Xu
-
Patent number: 10035790Abstract: Described are RORy modulators of the formula (I), and N-oxides thereof, and pharmaceutically acceptable salts thereof, and solvates and hydrates thereof, wherein R1, R2, R3, R4, R5, R6, Ra, x, y, L, G, Z, the bond denoted by “q”, the ring system denoted by “A” and the ring system denoted by “B” are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORy activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORy activity, for example, autoimmune and/or inflammatory disorders.Type: GrantFiled: October 17, 2013Date of Patent: July 31, 2018Assignees: Exelixis, Inc., Bristol-Myers Squibb Co.Inventors: Wei Xu, Yong Wang, Sunghoon Ma, Elena S. Koltun, Byung Gyu Kim, Joon Won Jeong, T. G. Murali Dhar, Lynne Canne Bannen
-
Publication number: 20150266856Abstract: Described are RORy modulators of the formula (I), and N-oxides thereof, and pharmaceutically acceptable salts thereof, and solvates and hydrates thereof, wherein R1, R2, R3, R4, R5, R6, Ra, x, y, L, G, Z, the bond denoted by “q”, the ring system denoted by “A” and the ring system denoted by “B” are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORy activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORy activity, for example, autoimmune and/or inflammatory disorders.Type: ApplicationFiled: October 17, 2013Publication date: September 24, 2015Inventors: Wei Xu, Yong Wang, Sunghoon Ma, Elena S. Koltun, Byung Gyu Kim, Joon Won Jeong, T.G. Muralii Dhar, Lynn Canne Bannen
-
Patent number: 8710038Abstract: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases. Methods of using the compounds and pharmaceutical compositions thereof to treat kinase-dependent diseases and conditions are also an aspect of the invention.Type: GrantFiled: September 15, 2005Date of Patent: April 29, 2014Assignee: Exelixis, Inc.Inventors: Tae-Gon Baik, Chris A. Buhr, Sunghoon Ma, John M. Nuss, Zerom Tesfai, Longcheng Wang, Bryan K. S. Yeung
-
Patent number: 8648066Abstract: The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.Type: GrantFiled: May 20, 2010Date of Patent: February 11, 2014Assignee: Exelixis, Inc.Inventors: Neel Kumar Anand, Charles M. Blazey, Owen Joseph Bowles, Chris Allen Buhr, Joerg Bussenius, Jeffry Kimo Curtis, Steven Charles DeFina, Larisa Dubenko, Jason R. Harris, Eileen E. Jackson-Ugueto, Anagha Joshi, Angie Inyoung Kim, Amy Lew Tsuhako, Sunghoon Ma, Jean-Claire Limun Manalo, Stephanie Ng, Csaba J. Peto, Kenneth D. Rice, Tsze H. Tsang, Cristiana A. Zaharia
-
Patent number: 8247408Abstract: The invention is directed to Compounds of Formula I and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.Type: GrantFiled: October 9, 2006Date of Patent: August 21, 2012Assignee: Exelixis, Inc.Inventors: Tae-Gon Baik, Chris A. Buhr, Katherine Lara, Sunghoon Ma, Longcheng Wang, Bryan K. S. Yeung
-
Patent number: 8101622Abstract: The invention is directed to Compounds of Formula I: optionally as a single stereoisomer or mixture of stereoisomers thereof, and additionally optionally as a pharmaceutically acceptable salt thereof; as well as methods of making and using the compounds.Type: GrantFiled: September 29, 2009Date of Patent: January 24, 2012Assignee: Exelixis, Inc.Inventors: Tae-Gon Baik, Sunghoon Ma, Chris A. Buhr, John M. Nuss
-
Patent number: 8044062Abstract: The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.Type: GrantFiled: October 9, 2006Date of Patent: October 25, 2011Assignee: Exelixis, Inc.Inventors: Tae-Gon Baik, Chris A. Buhr, Katherine Lara, Sunghoon Ma, Morrison Mac, John M. Nuss, Longcheng Wang, Yong Wang, Bryan K. S. Yeung
-
Publication number: 20110237608Abstract: The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.Type: ApplicationFiled: June 2, 2011Publication date: September 29, 2011Applicant: Exelixis, Inc.Inventors: Tae-Gon Baik, Chris A. Buhr, Katherine Lara, Sunghoon Ma, Morrison Mac, John M. Nuss, Longcheng Wang, Yong Wang, Bryan K.S. Yeung
-
Patent number: 8012956Abstract: A compound according to Formula I or II: wherein R1, R1b, R2, L1, and L2 and L2b are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.Type: GrantFiled: October 27, 2008Date of Patent: September 6, 2011Assignee: Exelixis, Inc.Inventors: Kenneth D. Rice, Naing Aay, Neel Kumar Anand, Arlyn Arcalas, Tae-Gon Baik, Charles M. Blazey, Owen Joseph Bowles, Chris A. Buhr, Joerg Bussenius, Simona Costanzo, Jeffrey Kimo Curtis, Steven Charles Defina, Larisa Dubenko, Abigail R. Kennedy, Angie Inyoung Kim, Katherine Lara, Sunghoon Ma, Jean-Claire Limun Manalo, Csaba J. Peto, Tsze H. Tsang, Longcheng Wang
-
Publication number: 20100305093Abstract: The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.Type: ApplicationFiled: April 8, 2010Publication date: December 2, 2010Applicant: EXELIXIS, INC.Inventors: Neel Kumar Anand, Arlyn Arcalas, Charles M. Blazey, Chris A. Buhr, Jonah Cannoy, Sergey Ephsteyn, Henry William Beecroft Johnson, Anagha Joshi, Byung Gyu Kim, James W. Leahy, Matthew Sangyup Lee, Sunghoon Ma, Morrison B. Mac, John M. Nuss, Craig Stacy Takeuchi, Longcheng Wang, Yong Wang
-
Publication number: 20100298290Abstract: The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.Type: ApplicationFiled: May 20, 2010Publication date: November 25, 2010Applicant: EXELIXIS, INC.Inventors: Neel Kumar Anand, Charles M. Blazey, Owen Joseph Bowles, Chris Allen Buhr, Joerg Bussenius, Jeffry Kimo Curtis, Steven Charles DeFina, Larisa Dubenko, Jason R. Harris, Eileen E. Jackson-Ugueto, Anagha Joshi, Angie Inyoung Kim, Amy Lew Tsuhako, Sunghoon Ma, Jean-Claire Limun Manalo, Stephanie Ng, Csaba J. Peto, Kenneth D. Rice, Tsze H. Tsang, Cristiana A. Zaharia
-
Publication number: 20100150827Abstract: The invention is directed to a Compound of Formula I, II, or III. The invention provides compounds that inhibit, regulate, and/or modulate PI3K that are useful in the treatment of hyperproliferatives diseases, such as cancer.Type: ApplicationFiled: April 11, 2008Publication date: June 17, 2010Applicant: Exelixis, IncInventors: Chris A. Buhr, William Bajjalieh, Anagha Abhijit Joshi, Katherine Lara, Sunghoon Ma, Charles K. Marlowe, Longcheng Wang, Bryan K.S. Yeung
-
Patent number: 7704995Abstract: This invention relates to compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion, and to pharmaceutical compositions containing such compounds. Even more specifically, the invention relates to compounds that inhibit, regulate and/or modulate kinases, particularly Checkpoint Kinases, even more particularly Checkpoint Kinase 1, or Chk1. Methods of therapeutically or prophylactically using the compounds and compositions to treat kinase-dependent diseases and conditions are also an aspect of the invention, and include methods of treating cancer, as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, by administering effective amounts of such compounds.Type: GrantFiled: May 2, 2003Date of Patent: April 27, 2010Assignee: Exelixis, Inc.Inventors: Chris A. Buhr, Tae-Gon Baik, Sunghoon Ma, Zerom Tesfai, Longcheng Wang, Erick Wang Co, Sergey Epshteyn, Abigail R Kennedy, Baili Chen, Larisa Dubenko, Neel Kumar Anand, Tsze H. Tsang, John M. Nuss, Csaba J Peto, Kenneth D. Rice, Mohamed Abdulkader Ibrahim, Kevin Luke Schnepp, Xian Shi, James William Leahy, Jeff Chen, Lisa Esther Dalrymple, Timothy Patrick Forsyth, Tai Phat Huynh, Grace Mann, Larry Wayne Mann, Craig Stacy Takeuchi, Peter Lamb, David J. Matthews, Nicole Miller
-
Publication number: 20100087456Abstract: The invention is directed to Compounds of Formula I: optionally as a single stereoisomer or mixture of stereoisomers thereof, and additionally optionally as a pharmaceutically acceptable salt thereof; as well as methods of making and using the compounds.Type: ApplicationFiled: September 29, 2009Publication date: April 8, 2010Applicant: Exelixis, Inc.Inventors: Tae-Gon Baik, Sunghoon Ma, Chris A. Buhr, John M. Nuss